pSivida has announced the availability of the sustained release pharmaceutical product indicated for the treatment of chronic diabetic macular edema (DME), Iluvien, in Germany. Alimera Sciences, pSivida's licensee, has reported the ...
Tags: pSivida Iluvien, Medicine
Canada-based biotechnology company Kane Biotech announced that DispersinB-Gentamicin combination wound gel spray has passed the primary skin irritation tests. The test was aimed at determining the dermal irritation potential of the spray ...
Tags: Dispersinb Combination, Skin Irritation Tests, Medicine
Zensah, a Miami based compression apparel company, has announced its plans to return to the 2013 Travel Goods Show in Las Vegas, Nevada. The TGS Show takes place February 27 to March 1 and attracts thousands of exhibitors and buyers from ...
Regeneron Pharmaceuticals and Bayer HealthCare have started a new Phase 3 VEGF Trap-Eye In Vision Impairment Due to DME (VIVID EAST-DME) trial of its Eylea (aflibercept) injection. Eylea, which is formulated as an iso-osmotic solution for ...
The US office of patents and trademarks has issued notice of allowance to Ampio Pharmaceuticals for diabetic macular edema (DME) drug Optina patent. The company has also received similar patent from the Canadian Intellectual Property ...
Tags: Ampio, allowance for DME drug, Optina patent
pSivida has completed enrolling first US patient in investigator-sponsored clinical trial of its injectable sustained release insert. pSivida president and CEO Ashton said the trial will study the use of injectable micro-inserts to treat ...
Tags: pSivida, clinical trial, injectable sustained release insert
The Federal Ministry of Health of Germany has granted marketing authorization to pSivida for injectable, sustained-release intravitreal insert, Iluvien, designed as a treatment for vision impairment associated with chronic diabetic macular ...
Tags: Psivida, DME, clinical product
The US Food and Drug Administration (FDA) has approved pSivida's investigational new drug (IND) application for injectable sustained-release micro-insert, designed as a treatment for posterior uveitis. pSivida's injectable ...
The European Commission (EC) has approved Bayer HealthCare's EYLEA (aflibercept solution for injection) at a recommended dose of 2 mg for the treatment of wet age-related macular degeneration (wet AMD). Formulated as an iso-osmotic ...
Tags: European Commission, Bayer, Aflibercept Solution, EYLEA
The National Security Agency of Medicines and Health Products in France has granted marketing authorization to pSivida's ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME). The injectable, ...
Sagent Pharmaceuticals has introduced Acetazolamide for Injection, USP specified for adjunctive treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies and chronic simple glaucoma, secondary ...
Tags: Acetazolamide Injection, adjunctive treatment, Pharmaceuticals
UK-based Medicines and Healthcare products Regulatory Agency(MHRA)has granted marketing authorization to pSivida for its Iluvien insert. The marketing authorization follows the recently announced approval in Austria. The approvals were ...
Tags: pSivida Iluvien insert, MHRA, intravitreal insert, Iluvien
US-based Esaote has launched a new Weight-Bearing MRI system to increase diagnostic accuracy while performing musculoskeletal MRI examinations. Featuring a touch screen display on the gantry, the G-scan Brio system's tilting MRI provides ...
Tags: Weight-Bearing MRI system, Esaote
Genentech, a member of Roche Group, has obtained clearance for its Lucentis 0.3 mg (ranibizumab injection) from the US Food and Drug Administration (FDA). Lucentis 0.3 mg is a recombinant humanized monoclonal antibody fragment (lacking an ...
Tags: Genentech, Lucentis 0.3 mg, Medicine, Injection
Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin has signed a co-promotion agreement with Santen Pharmaceutical for Eylea (aflibercept) injection in Japan. Eylea is approved for sale in the US and Australia for the treatment of ...